Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Catalyst Pharmaceuticals Inc Stock Research

CPRX

12.14USD+0.01(+0.08%)Market Closed
Watchlist

Market Summary

USD12.14+0.01
Market Closed
0.08%

CPRX Alerts

CPRX Stock Price

CPRX RSI Chart

CPRX Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

11.19

Price/Sales (Trailing)

4.27

EV/EBITDA

7.68

Price/Free Cashflow

10.42

CPRX Price/Sales (Trailing)

CPRX Profitability

EBT Margin

48.57%

Return on Equity

29.79%

Return on Assets

24.41%

Free Cashflow Yield

9.6%

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

302.9M

Revenue Y/Y

87.49%

Revenue Q/Q

16.65%

CPRX Earnings

Earnings (TTM)

115.5M

Earnings Y/Y

74.67%

Earnings Q/Q

27.71%

Price Action

52 Week Range

11.0922.11
(Low)(High)

Last 7 days

-3.9%

Last 30 days

-14.8%

Last 90 days

-7.6%

Trailing 12 Months

2.2%

CPRX Financial Health

Current Ratio

3.51

CPRX Investor Care

Shares Dilution (1Y)

3.60%

Diluted EPS (TTM)

1.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CPRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-03
DENKHAUS DONALD A
acquired
67,800
1.13
60,000
-
2023-06-27
Del Carmen Jeffrey
acquired
-
-
10,000
chief commercial officer
2023-06-27
Del Carmen Jeffrey
sold (taxes)
-
-
-3,942
chief commercial officer
2023-05-16
MCENANY PATRICK J
acquired
137,341
0.79
173,849
president and ceo
2023-05-15
MCENANY PATRICK J
sold
-345,978
13.23
-26,151
president and ceo
2023-05-15
MCENANY PATRICK J
acquired
20,659
0.79
26,151
president and ceo
2023-05-12
Daly Richard J
acquired
39,500
0.79
50,000
-
2023-05-11
Tierney David S
acquired
15,800
0.79
20,000
-
2023-05-11
Miller Steve
acquired
79,000
0.79
100,000
chief operating officer
2023-05-04
COELHO PHILIP H
acquired
39,500
0.79
50,000
-

1–10 of 50

Which funds bought or sold CPRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
241
5,693,000
8,907,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
-1,783
7,634
-%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
reduced
-55.56
-4,773
2,688
-%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-312,056
1,335,680
0.01%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
50.9
165,044
904,512
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.08
-420,392
1,618,140
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
5.57
-71,000
423,000
-%
2023-08-21
VisionPoint Advisory Group, LLC
new
-
42,685
42,685
0.02%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-23.23
-292,951
482,550
-%
2023-08-17
Orion Portfolio Solutions, LLC
added
29.6
8,934
185,660
-%

1–10 of 47

Latest Funds Activity

Are funds buying CPRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CPRX
No. of Funds

Schedule 13G FIlings of Catalyst Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
armistice capital, llc
0%
0
SC 13G/A
Feb 10, 2023
flynn james e
5.65%
5,884,448
SC 13G/A
Feb 09, 2023
vanguard group inc
6.50%
6,768,741
SC 13G
Feb 08, 2023
state street corp
7.57%
7,873,314
SC 13G/A
Jan 26, 2023
blackrock inc.
15.1%
15,690,326
SC 13G/A
Jan 20, 2023
blackrock inc.
15.1%
15,690,326
SC 13G/A
Nov 14, 2022
flynn james e
5.82%
6,060,491
SC 13G
Feb 15, 2022
armistice capital, llc
9.3%
9,572,000
SC 13G/A
Feb 09, 2022
vanguard group inc
4.69%
4,836,313
SC 13G/A
Feb 09, 2022
state street corp
4.90%
5,050,989
SC 13G/A

Recent SEC filings of Catalyst Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 08, 2023
S-3ASR
S-3ASR
Aug 25, 2023
8-K
Current Report
Aug 09, 2023
8-K
Current Report
Aug 09, 2023
10-Q
Quarterly Report
Aug 04, 2023
4
Insider Trading
Jul 28, 2023
8-K
Current Report
Jul 21, 2023
8-K
Current Report
Jul 17, 2023
ARS
ARS
Jul 12, 2023
DEF 14A
DEF 14A
Jun 29, 2023
4
Insider Trading

Peers (Alternatives to Catalyst Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
272.0B
56.0B
5.43% 9.20%
31.31
4.85
-2.31% -31.27%
255.4B
1.8B
-4.05% 37.32%
-147.41
141.03
69.45% 14.65%
90.7B
9.5B
0.17% 23.71%
26.94
9.54
13.83% 5.33%
89.1B
12.7B
0.52% 19.69%
20.72
7.03
-10.94% -24.40%
21.9B
1.2B
-9.77% -14.95%
-20.56
17.67
39.94% -8.44%
11.1B
1.0B
-3.58% 6.05%
-12.27
11.1
20.15% -79.16%
10.8B
2.1B
-2.16% 7.92%
12.38
5.11
18.01% 38.16%
MID-CAP
3.0B
225.6M
-2.45% -24.77%
-5.46
13.42
-2.11% 21.02%
2.8B
-
-15.83% 131.72%
-8.45
-
- -28.88%
2.6B
402.9M
-3.27% -11.64%
-3.64
6.51
20.50% -42.46%
2.4B
27.2M
11.70% -39.35%
-3.27
88.62
- -14.43%
SMALL-CAP
3.1B
-
-14.00% -40.97%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-14.82% 2.19%
11.19
4.27
77.72% 112.02%
284.9M
152.5M
-8.91% 51.32%
38.25
1.87
127.84% 103.41%
28.4M
-
-10.88% 3445.93%
-0.62
-
- -31.51%

Catalyst Pharmaceuticals News

MarketWatch
Catalyst Pharmaceuticals Inc. stock rises Tuesday, outperforms market.
MarketWatch,
3 hours ago
StreetInsider.com
Form 487 FT 10968.
StreetInsider.com,
32 hours ago
StockNews.com
StockNews.com

Returns for CPRX

Cumulative Returns on CPRX

14.2%


10-Year Cumulative Returns

39.7%


7-Year Cumulative Returns

26.7%


5-Year Cumulative Returns

56.6%


3-Year Cumulative Returns

Risks for CPRX

What is the probability of a big loss on CPRX?

90.8%


Probability that Catalyst Pharmaceuticals stock will be more than 20% underwater in next one year

67.7%


Probability that Catalyst Pharmaceuticals stock will be more than 30% underwater in next one year.

63.1%


Probability that Catalyst Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CPRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalyst Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Catalyst Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42010Q4
Revenue18.1%30325621419217015414113412712011911812011910273.0056.0026.002.000.00
Operating Expenses20.8%16513611210898.0094.0088.0084.0082.0082.0078.00-----55.0043.0036.00-
  S&GA Expenses21.7%87.0071.0058.0057.0055.0053.0050.0050.0048.0047.0044.0042.0040.0039.0037.0032.0028.0022.0016.00-
  R&D Expenses-0.1%20.0020.0020.0021.0017.0017.0017.0016.0015.0015.0016.0019.0019.0020.0019.0021.0021.0020.0020.00-
EBITDA-100.0%-12510585.0073.0060.0053.0049.0046.0041.0042.0042.0044.0045.0033.0011.00----
EBITDA Margin-100.0%-0.49*0.49*0.44*0.43*0.39*0.38*0.37*0.37*0.34*0.35*0.35*0.37*0.38*0.33*0.14*----
Earnings Before Taxes16.3%14512510585.0073.0060.0053.0049.0046.0041.0042.0042.0044.0045.0033.0011.00-11.57-28.95-34.00-
EBT Margin-100.0%-0.49*0.49*0.44*0.43*0.39*0.37*0.36*0.36*0.34*0.35*0.35*0.37*0.38*0.33*0.14*----
Net Income16.2%11699.0083.0067.0054.0045.0039.0042.0075.0072.0075.0071.0042.0043.0032.009.00-12.02-28.95-34.00-
Net Income Margin-100.0%-0.39*0.39*0.35*0.32*0.29*0.28*0.31*0.59*0.60*0.63*0.60*0.35*0.36*0.31*0.13*----
Free Cashflow-100.0%-12011695.0075.0064.0059.0053.0043.0040.0045.0044.0049.0050.0035.0014.00----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets9.0%44440737633326724723822320919719217513111811297.0078.0061.0060.0068.0074.00
  Current Assets21.1%24119932127624322121019317616215914313111711191.0072.0055.0055.0062.0069.00
    Cash Equivalents20.6%17914829825621117817115513512713011711510290.0045.0023.0019.0017.0011.0010.00
  Inventory4.1%11.0010.007.007.008.008.008.007.007.004.005.005.002.002.002.001.000.000.000.00--
  Net PPE-6.4%1.001.001.001.001.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-6.7%69.0074.0075.0063.0026.0027.0031.0025.0020.0019.0023.0018.0020.0018.0025.0019.0015.0010.0010.004.003.00
  Current Liabilities-7.4%53.0057.0058.0045.0022.0023.0027.0021.0016.0014.0023.0018.0020.0018.0024.0018.0014.009.0010.003.003.00
Shareholder's Equity12.5%37533430027024122020719918917917015711110088.0078.0063.0051.0051.0064.0071.00
  Retained Earnings47.5%11779.0050.0024.002.00-15.62-26.31-32.54-37.82-46.33-53.70-65.14-108-118-128-136-150-161-160-146-138
  Additional Paid-In Capital1.5%258254250246239236233231227225223222220218216214213212211210209
Shares Outstanding0.5%107106105104103103103103103104104104103103103103103103103103103
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations3.8%12412011695.0076.0065.0060.0054.0044.0042.0045.0044.0049.0050.0035.0014.00-9.25-28.08-26.15-21.83-17.51
  Share Based Compensation14.3%10.009.008.007.007.006.006.006.006.006.006.006.005.004.004.004.004.004.004.003.003.00
Cashflow From Investing25.0%-162-2169.00-0.35-0.22--11.02-10.98-20.92-16.92-5.0127.0042.0032.0037.0020.0022.0027.00-15.08-29.17-36.77
Cashflow From Financing81.9%6.003.002.00-3.08-9.17-9.88-8.14-5.59-2.881.001.001.001.001.001.001.001.000.000.0054.0056.00
  Buy Backs-100.0%-4.007.0010.0015.0014.0012.0012.008.001.00-----------

CPRX Income Statement

2023-06-30
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 99,582$ 53,113$ 184,948$ 96,202
Operating costs and expenses:    
Cost of sales[1]12,0457,64321,99113,533
Research and development3,9543,9837,5167,386
Selling, general and administrative[1]28,39612,91858,11429,348
Amortization of intangible assets8,488015,0190
Total operating costs and expenses52,88324,544102,64050,267
Operating income46,69928,56982,30845,935
Other income (expense), net1,813(324)3,517(231)
Net income before income taxes48,51228,24585,82545,704
Income tax provision10,7506,62618,49510,844
Net income$ 37,762$ 21,619$ 67,330$ 34,860
Net income per share:    
Basic$ 0.36$ 0.21$ 0.64$ 0.34
Diluted$ 0.33$ 0.2$ 0.59$ 0.32
Weighted average shares outstanding:    
Basic106,258,790102,795,600105,911,936102,788,719
Diluted113,673,534109,264,730113,840,155109,149,185
Net income$ 37,762$ 21,619$ 67,330$ 34,860
Other comprehensive income (Note 4):    
Unrealized gain (loss) on available-for-sale securities, net of tax of ($3), ($101), $2 and $2, respectively8323(5)18
Comprehensive income37,77021,94267,32534,878
Product revenue, net [Member]    
Revenues:    
Total revenues99,47753,049184,78196,082
License and other revenue [Member]    
Revenues:    
Total revenues$ 105$ 64$ 167$ 120
[1]exclusive of amortization of intangible assets

CPRX Balance Sheet

2023-06-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 178,787$ 298,395
Accounts receivable, net42,79610,439
Inventory10,7516,805
Prepaid expenses and other current assets8,6345,167
Total current assets240,968320,806
Operating lease right-of-use asset2,6412,770
Property and equipment, net1,203847
License and acquired intangibles, net175,59532,471
Deferred tax assets, net23,48918,736
Total assets443,896375,630
Current Liabilities:  
Accounts payable4,4213,975
Accrued expenses and other liabilities48,08253,613
Total current liabilities52,50357,588
Operating lease liability, net of current portion3,3763,557
Other non-current liabilities12,72314,064
Total liabilities68,60275,209
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at June 30, 2023 and December 31, 202200
Common stock, $0.001 par value, 200,000,000 shares authorized; 106,501,259 shares and 105,263,031 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively107105
Additional paid-in capital257,976250,430
Retained earnings117,19249,862
Accumulated other comprehensive income (loss) (Note 4)1924
Total stockholders' equity375,294300,421
Total liabilities and stockholders' equity$ 443,896$ 375,630
Patrick J. McEnany
80
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.